KRAS, NRAS, BRAF mutation testing: best clinics abroad

KRAS, NRAS and BRAF mutation testing examines genetic changes in tumour cells. In colorectal cancer, these results can inform treatment assessment, but RAS status and BRAF findings answer different clinical questions. The exact alteration matters: a gene name or a simple positive result is not enough to select treatment. Testing complements the pathology diagnosis and staging; it does not establish that a particular therapy will work.

Ask your oncologist which analyses are needed now and whether earlier reports already cover the relevant gene regions. Material from a previous biopsy or operation may be suitable after laboratory review. Before arranging testing at another centre, clarify the sample requirements, scope of the panel, reporting format and complete quotation. Send the pathology report and treatment history with existing biomarker results so the team can check for missing information. If a blood-based test is proposed, discuss its limitations and the plan for tissue assessment if the result is negative or uninformative.

RAS and BRAF answer different questions

These genes participate in cell signalling, but their findings are not interchangeable.

• KRAS and NRAS: together these contribute to RAS status in colorectal cancer. Expanded RAS testing covers relevant regions of both genes. RAS status informs consideration of EGFR-directed antibody treatment; the exact variant may have additional implications.
• BRAF: testing identifies alterations such as V600E. A BRAF finding can add information about tumour biology and treatment options. Its meaning depends on the specific variant and cancer type.

Choosing and checking the sample

The laboratory may use stored tumour material from a biopsy or operation. A pathologist should assess tumour content and sample quality before analysis. If the material is insufficient, the team should discuss another sample or testing approach. Ask the receiving laboratory which blocks or slides it accepts, what documentation is required, and how material will be transferred and returned.

Reading the report in context

Look for the genes and regions assessed, the method, the exact variants found and any limitations. A result from a narrow assay is not equivalent to a comprehensive molecular profile. In colorectal cancer, other markers such as mismatch repair or microsatellite instability status also matter. Your oncologist should combine results with stage, pathology, prior treatment and your health. An identified target does not guarantee benefit.

Limits of a blood-based test

Liquid biopsy can detect selected tumour-derived genetic changes in blood when appropriate. A negative result does not rule out all alterations in the tumour. Ask whether tissue testing or further assessment is needed, particularly when the blood result does not answer the clinical question. The tests are not automatically interchangeable.

Planning testing and follow-up

Request a quotation naming the genes, methods and any wider panel included. Check separately for pathology review, specimen retrieval, transport, translation and consultation fees. Ask when reporting is expected after the sample is accepted and what happens if analysis is unsuccessful. Arrange an oncology consultation to discuss the complete report and any remaining testing needs.

Frequently asked questions

What does RAS wild type mean?

It usually means no relevant RAS mutation was detected within the regions tested. Check the assay coverage and report limitations; this finding alone does not determine treatment.

Does tumour testing show inherited cancer risk?

Its main purpose here is to assess tumour alterations, rather than inherited predisposition. Family history or particular findings may prompt separate genetic counselling and germline testing.

Is BRAF interpreted the same way in every cancer?

No. A BRAF variant in colorectal cancer can have different treatment implications from one in melanoma or another tumour. Interpretation must use the correct cancer context and exact variant.